Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Compassionate Use of Daptomycin for Resistant Gram-Positive Infections
NCT00055198Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Dec 2002
- Primary completion
- Jan 2004
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of daptomycin in Gram-positive bacterial infections, sponsored by Merck & Co. Started Dec 2002; status: terminated.
02
Drugs
daptomycin
03
Conditions
Gram-positive bacterial infections
Beyond the preview
Go deeper on NCT00055198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00055198.